HRP20140681T1 - Novi spojevi korisni za lijeäśenje degenerativnih i upalnih bolesti - Google Patents

Novi spojevi korisni za lijeäśenje degenerativnih i upalnih bolesti Download PDF

Info

Publication number
HRP20140681T1
HRP20140681T1 HRP20140681AT HRP20140681T HRP20140681T1 HR P20140681 T1 HRP20140681 T1 HR P20140681T1 HR P20140681A T HRP20140681A T HR P20140681AT HR P20140681 T HRP20140681 T HR P20140681T HR P20140681 T1 HRP20140681 T1 HR P20140681T1
Authority
HR
Croatia
Prior art keywords
pyridin
triazolo
phenyl
cyclopropanecarboxamide
amide
Prior art date
Application number
HRP20140681AT
Other languages
English (en)
Inventor
Christel Jeanne Marie Menet
Luc Juliaan Corina Van Rompaey
Stephen Robert Fletcher
Javier Blanc
Nolwenn Jouannigot
Alastair James Hodges
Koen Kurt Smits
Original Assignee
Galapagos N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos N.V. filed Critical Galapagos N.V.
Publication of HRP20140681T1 publication Critical patent/HRP20140681T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (11)

1. Spoj prema Formuli III: [image] naznačen time da L1 je odabran od jednostruke veze, -O-, -N(R4a)-, -C(O)-, C[=N(R4a)]-, -CON(R4a)-, -SO2N(R4a)-, -S(O)2-, -N(R4a)SO2- i -N(R4a)CO-; n1 je 0, 1, 2, 3, ili 4; i R3b je supstituiran ili nesupstituiran C6-10 aril, supstituiran ili nesupstituiran 5-10 člani heteroaril koji sadrži 1 do 3 heteroatoma odabrana od N, O, ili S, supstituiran ili nesupstituiran C3-C7 cikloalkil, supstituiran ili nesupstituiran 4-7 člani heterocikloalkil koji sadrži 1 do 3 heteroatoma odabrana od N, O, ili S, R4a je H, supstituiran ili nesupstituiran C1-C4 alkil, supstituiran ili nesupstituiran C1-C4 alkoksi, pri čemu su supstituenti za izraz "supstituiran" u definiciji R3b, i R4a odabrani iz skupine koja sadrži: halo, cijano, nitro, trifluorometil, trifluorometoksi, azido, -NR"'SO2R', -SO2NR"R''', -C(O)R",-C(O)OR", -OC(O)R", -NR'"C(O)R", -C(O)NR"R"', -NR'R"', -(CR"'R"')mOR"', pri čemu, svaki R" je neovisno odabran od H, C1-C8 alkil, -(CH2)t(C6-C10 aril), -(CH2)t(5-10 člani heteroaril koji sadrži 1 do 3 heteroatoma odabrana od N, O, ili S), -(CH2)t(C3-C10 cikloalkil), i -(CH2)t(4-10 člani heterocikloalkil koji sadrži 1 do 3 heteroatoma odabrana od N, O, ili S), pri čemu t je cijeli broj od 0 do 4; i • bilo koje alkil skupine koje su prisutne, mogu i same biti supstituirane s halo ili hidroksi; i • bilo koje aril, heteroaril, cikloalkil ili heterocikloalkil skupine koje su prisutne, mogu i same biti supstituirane s nesupstituiranim C1-C4 alkilom, halo, nesupstituiranim C1-C4 alkoksi, nesupstituiranim C1-C4 haloalkilom, nesupstituiranim C1-C4 hidroksialkilom, ili nesupstituiranim C1-C4 haloalkoksi ili hidroksilom; svaki R"' neovisno predstavlja H ili C1-C6alkil; i uz uvjet da i) kada L1 je -O-, -N(R4)-, -CON(R4a)-, ili -SO2N(R4a)-, i R3b je različit od cikloalkila, arila ili 5-10 članog heteroarila, tada n1 je 1, 2, 3, ili 4; ili njihova farmaceutski prihvatljiva sol, za uporabu za liječenje i/ili sprječavanje - reumatoidnog artritisa, osteoartritisa, alergijskih bolesti dišnih puteva, upalnih bolesti crijeva - kronične opstruktivne plućne bolesti, astme, sistemskog eritemskog lupusa - Castlemanove bolesti ili mezangijskog proliferativnog glomerulonefritisa endotoksinom pokretanih bolesnih stanja, bolesti koje uključuju pogoršanje promjena u hrskavici, kongenitalnih malformacija hrskavice, te odbacivanja transplantata.
2. Spoj za uporabu prema zahtjevu 1, naznačen time da -Ph-L1-(CH2)n1-R3b je odabran od: [image] [image] pri čemu n2 je n1; i R3b, i n1 su kako je opisano u zahtjevu 1; i Cy3 je supstituiran ili nesupstituiran dušik koji sadrži 4-7-članu heterocikloalkil skupinu.
3. Spoj za uporabu prema zahtjevu 1 ili 2, naznačen time da R3b je odabran od: [image] [image] [image] [image] pri čemu svaki R5a je neovisno C1-C4 alkil, halo, CF3 ili fenil; R5b je H, C6-10aril, 5-10 člani heteroaril koji sadrži 1 do 3 heteroatoma odabrana od N, O, ili S, C3-C6 cikloalkil, ili 4-7 člani heterocikloalkil koji sadrži 1 do 3 heteroatoma odabrana od N, O, ili S; i m5 je 0, 1 ili 2.
4. Spoj za uporabu prema zahtjevu 1 ili 2, naznačen time da R3b je odabran od: [image] [image] [image] pri čemu svaki R5a je neovisno C1-C4 alkil, halo, CF3 ili fenil; R5b je H, C6-10 aril, 5-10 člani heteroaril koji sadrži 1 do 3 heteroatoma odabrana od N, O, ili S, C3-C6 cikloalkil, ili 4-7 člani heterocikloalkil; R5c je H, ili C1-C4 alkil; m5 je 0, 1, ili 2; n5 je 0, 1, ili 2.
5. Spoj za uporabu prema zahtjevu 1 ili 2, naznačen time da je spoj prema bilo kojoj od formula Va, Vb, Vc, ili Vd: [image]
6. Spoj za uporabu prema zahtjevu 1 ili 2, naznačen time da je spoj prema bilo kojoj od formula VIa, VIc, VId: [image]
7. Spoj za uporabu prema zahtjevu 1 ili 2, naznačen time da je spoj prema bilo kojoj od formula VIIa, VIIb, VIIc, VIId, VIIe, VIIf: [image] [image]
8. Spoj za uporabu prema zahtjevu 1, naznačen time da je spoj odabran iz skupine koja sadrži: N-(5-(4-(4-metilpiperazin-1-il)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(3-(morfolinometil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(bifenil-4-il)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-benzoilfenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-ciklopropilbenzamid N-(5-(4-(benziloksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(N-ciklopropilsulfamoil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(3-(benziloksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(benziloksi)-3-fluorofenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(2-(benziloksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(piperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(morfolinometil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(pirolidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(tiofen-2-il)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)fenil)benzamid N-(4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)fenil)-4-(trifluorometil)benzamid N-(5-(4-(2-fenilacetamido)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(morfolin-4-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-(piridin-4-il)benzamid N-cikloheksil-4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)benzamid N-(5-(4-(4-tert-butilpiperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(1,4-diazepan-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-(3-fluorobenzil)benzamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-metil-N-fenilbenzamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-(4-metoksibenzil)-N-metilbenzamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-(1-metilpiperidin-4-il)benzamid N-(5-(4-(4-fluorofenilsulfonamido)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)fenil)-2-fluorobenzamid N-(4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)fenil)pirazin-2-karboksamid N-(5-(4-(piridin-3-ilmetoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(piridin-2-ilmetoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(3-(trifluorometoksi)benziloksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(ciklobutilmetoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(ciklopentiloksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(cikloheksilmetoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-(piridin-3-ilmetil)benzamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-fenilbenzamid N-(5-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)piridin-2-il)benzamid N-(4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)fenil)cikloheksankarboksamid N-(5-(4-fenoksifenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((1-metil-1H-pirazol-3-il)metilmetil-1H-pirazol-3-il)metoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((3,5-dimetilizoksazol-4-il)metoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((1,3-dimetil-1H-pirazol-5-il)metildimetil-1H-pirazol-5-il)metoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(2-(3,5-dimetil-1H-pirazol-4-il)etildimetil-1H-pirazol-4-il)etoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((5-metilizoksazol-3-il)metoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)fenil)-3-metoksibenzamid N-(5-(4-(2-fluorofenilsulfonamido)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)fenil)pikolinamid N-benzil-4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)benzamid N-(5-(4-(1,2,3,4-tetrahidroizokinolin-2-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(ciklopropansulfonamido)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-(2-fenoksietil)benzamid N-(5-(4-((1,5-dimetil-1H-pirazol-3-il)metildimetil-1H-pirazol-3-il)metoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((2,5-dimetiloksazol-4-il)metoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(piridin-3-sulfonamido)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(1,3-dimetil-1H-pirazol-4-sulfonamido)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(piridin-3-il)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropropankarboksamid N-(5-(4-(1H-pirazol-4-il)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)fenil)-1-metil-3-propil-1H-pirazol-5-karboksamid N-(4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)fenil)ciklobutankarboksamid N-(5-(4-(4-metilpiperazin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(benzilamino)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(4-(etoksimetil)piperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(4-benzoilpiperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(4-benzil-1,4-diazepan-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(2-feniletilsulfonamido)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(fenilmetilsulfonamido)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((6-(trifluorometil)piridin-3-il)metoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(fenilsulfonamido)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-(2-(pirolidin-1-il)etil)benzamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-(3-morfolinopropil)benzamid N-(5-(4-(4-propilfenilsulfonamido)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(4-(4-klorofenil)piperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-fenetilbenzamid N-(5-(4-(2-(3-fluorofenil)etilsulfonamido)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(2-fluoro-4-(piperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-butil-4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-(3-morfolinopropil)benzamid N-(5-(4-((2-(4-(trifluorometil)fenil)tiazol-4-il)metoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(4-acetamidobenziloksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(6-(2-(tetrahidro-2H-piran-4-il)etilamino)piridin-3-il)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(4-(2-morfolinoetil)piperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-metil-N-fenetilbenzamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-(4-(trifluorometil)fenetil)benzamid N-(5-(4-(2-(1H-pirazol-1-il)etil1H-pirazol-1-il)etoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((1,2,4-oksadiazol-3-il)metoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-3-fluoro-N-(2-fenoksietil)benzamid N-(5-(4-(4-morfolinopiperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-(2-metil-1-morfolinopropan-2-il)benzamid N-(5-(4-(4-(benzil(metil)amino)piperidin-1-karbonil)fenil)[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-(3,4-dimetoksifenetil)-N-metilbenzamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-(2-(1-fenil-1H-pirazol-4-il)etil)benzamid N-(5-(4-(3-fenoksipropanamido)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(3-fenilpropanamido)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(4-piridin-3-iloksi)piperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-3-fluoro-N-fenetilbenzamid N-(5-(4-(4-(3-klorofenil)piperazin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-(3-fenilpropil)benzamid N-(5-(4-(2-(4-fluorofenoksi)etoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(2-(3-fluorofenilamino)-2-oksoetoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(2-okso-2-(piperidin-1-il)etoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(2-(metil(fenil)amino)-2-oksoetoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid (S)-N-(1-benzilpirolidin-3-il)-4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)benzamid (R)-N-(1-benzilpirolidin-3-il)-4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)benzamid N-(5-(4-(2-fenoksietilsulfonamido)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-(2-(piridin-3-il)etil)benzamid N-(5-(4-(1H-pirazol-1-il)benziloksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(4-((4-metilpiperazin-1-il)metil)benziloksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(2-(piridin-3-il)etoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(4-(1H-benzo[d]imidazol-2-il)piperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-morfolinofenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((4-metilpiperazin-1-il)metil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(4-(2-metoksifenil)piperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(4-(4-klorofenil)-4-hidroksipiperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(4-(o-toliloksimetil)piperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(3,5-dimetilpiperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-izopropil-N-(4-(piperidin-1-il)benzil)benzamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-propil-N-((tetrahidrofuran-2-il)metil)benzamid N-(5-(4-(4-fluoropiperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(4-(1H-indol-2-il)piperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(piperidin-1-ilmetil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid 1-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)benzil)piperidin-4-karboksamid N-(5-(4-((4-acetoilpiperazin-1-il)metil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((4-(piridin-2-il)piperazin-1-il)metil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((4-(pirimidin-2-il)piperazin-1-il)metil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(2-metilpiperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(3-metilpiperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(4-metilpiperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(4-fenetilpiperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(4-(trifluorometil)piperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(4-(6-fluorobenzo[d]izoksazol-3-il)piperidin-1-karbonil)fenil)-1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-benzil-4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-(2-(dimetilamino)etil)benzamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-(4-fluorobenzil)-N-(1-metoksipropan-2-il)benzamid N-(5-(4-(4-(1H-benzo[d][1,2,3]triazol-1-il)piperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid 4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-(4-fluorobenzil)-N-((tetrahidrofuran-2-il)metil)benzamid N-(5-(4-(imino(4-(2-(2-metil-1H-imidazol-1-il)etil)piperidin-1-il)metil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((metil(2-(piridin-2-il)etil)amino)metil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(4-benzil-4-hidroksipiperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(benzil(metil)amino)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((1H-tetrazol-5-il)metil1H-tetrazol-5-il)metoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((metil(4-(piridin-2-il)benzil)amino)metil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((((1,5-dimetil-1H-pirazol-3-il)metil)(metil)amino)metil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((metil(4-(pirimidin-5-il)benzil)amino)metil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(metil(piridin-3-ilmetil)amino)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(benziloksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)acetamid N-(5-(4-(3-(trifluorometil)piperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((6-morfolinopiridin-3-il)metoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((6-(1H-pirazol-4-il)piridin-3-il)metil1H-pirazol-4-il)piridin-3-il)metoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((6-(4-metilpiperazin-1-il)piridin-3-il)metoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(4,4-difluoropiperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(3-fenilpiperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((6-(pirolidin-1-il)piridin-3-il)metoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(3,3-dimetilpiperidin-1-karbonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((6-cijanopiridin-3-il)metoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid 1-cijano-N-(4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)fenil)ciklopropankarboksamid N-(5-(4-((6-(1-metil-1H-pirazol-4-il)piridin-3-il)metilmetil-1H-pirazol-4-il)piridin-3-il)metoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(cijanometil)-4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)-N-fenetilbenzamid N-(5-(4-(piridin-3-ilmetilamino)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-((6-(1H-tetrazol-5-il)piridin-3-il)metil1H-tetrazol-5-il)piridin-3-il)metoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(1-(piridin-2-il)etoksi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid Metil 6-((4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)fenilciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)fenoksi)metil)nikotinat 5-((4-(2-(ciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)fenilciklopropankarboksamido)-[1,2,4]triazolo[1,5-a]piridin-5-il)fenoksi)metil)pikolinamid N-(5-(1-(piridin-2-ilmetil)-1H-1,2,3-triazol-4-il)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(piridin-2-ilmetilsulfonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid N-(5-(4-(piridin-3-ilmetilsulfonil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciklopropankarboksamid {5-[4-(1-hidroksi-piridin-3-ilmetoksi)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(6-metil-piridin-3-ilmetoksi)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(6-kloro-piridin-3-ilmetoksi)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(1-metil-1H-[1,2,4]triazol-3-ilmetoksi)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(1,1-diokso-tiomorfolin-4-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline (5-{4-[2-(3,5-dimetil-izoksazol-4-il)-etoksi]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline {5-[4-(acetil-piridin-3-ilmetil-amino)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline 4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-N-(6-metoksi-piridin-3-il)-benzamid 4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-N-(6-morfolin-4-il-piridin-3-il)-benzamid 4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-N-[6-(4-metil-piperazin-1-il)-piridin-3-il]-benzamid 4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-N-piridin-3-il-benzamid {5-[4-(acetil-piridin-2-ilmetil-amino)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(4-hidroksi-piperidin-1-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(4-cijano-piperidin-1-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(2-piridin-2-il-etil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline (5-{4-[(4-kloro-2-fluoro-fenilamino)-metil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline {5-[4-(3,3-dimetil-morfolin-4-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-((2R,6S)-2,6-dimetil-morfolin-4-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(2,6-dimetil-morfolin-4-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(3,3-dimetil-morfolin-4-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-((1S,4S)-2-oksa-5-aza-biciklo[2.2.1]heptan-5-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline 4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-N-(5-ciklopropil-2-metil-2H-pirazol-3-il)-benzamid (5-{4-[4-(morfolin-4-karbonil)-piperidin-1-karbonil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline {5-[4-(4-acetil-piperazin-1-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline 4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-N-piridazin-3-il-benzamid {5-[4-(piridazin-3-ilaminometil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(piridin-3-ilaminometil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline (5-{4-[(4-cijanometil-fenilamino)-metil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline (5-{4-[(2-cijanometil-fenilamino)-metil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline (5-{4-[(2-fluoro-fenilamino)-metil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline 4-{4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-benzilamino}-benzamid 3-{4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-benzilamino}-benzamid {5-[4-(pirimidin-2-ilaminometil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline (5-{4-[(1S,4S)-1-(2-oksa-5-aza-biciklo[2.2.1]hept-5-il)metil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline {5-[4-(2-fenil-morfolin-4-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(4-cijano-piperidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(4-fluoro-piperidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(4,4-difluoro-piperidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline [5-(4-{[6-(4-metil-piperazin-1-il)-piridin-3-ilamino]-metil}-fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il]-amid ciklopropankarboksilne kiseline (5-{4-[(6-metoksi-piridin-3-ilamino)-metil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline (5-{4-[(6-morfolin-4-il-piridin-3-ilamino)-metil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline [5-(4-fenoksimetil-fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il]-amid ciklopropankarboksilne kiseline {5-[4-(6-cijano-piridin-3-il)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(4-trifluorometil-piperidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline (5-{4-[4-(2,2,2-trifluoro-etil)-piperazin-1-ilmetil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline {5-[4-(4-hidroksi-piperidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline (5-{4-[4-(1-hidroksi-1-metil-etil)-piperidin-1-ilmetil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline {5-[4-(piridin-2-ilaminometil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline (5-{4-[(2,4-difluoro-3-metoksi-fenilamino)-metil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline (5-{4-[(2,6-difluoro-fenilamino)-metil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline {5-[4-(4-dietilamino-piperidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline (5-{4-[(2-fluoro-5-trifluorometil-fenilamino)-metil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline 3-{4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-benzilamino}-4-metil-benzamid {5-[4-(4-hidroksimetil-piperidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline 3-{4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-benziloksi}-benzamid {5-[4-(3-dietilamino-pirolidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-((1R,4R)-5-etil-2,5-diaza-biciklo[2.2.1]hept-2-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(3-okso-morfolin-4-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline 3-{4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-benzilamino}-4-metoksi-benzamid (5-{4-[(2-fluoro-6-metil-piridin-3-ilamino)-metil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline (5-{4-[(3,5-difluoro-piridin-2-ilamino)-metil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline (5-{4-[(4-cijano-2-fluoro-fenilamino)-metil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline (5-{4-[(2-fluoro-4-metil-fenilamino)-metil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline [5-(4-pirolidin-1-ilmetil-fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il]-amid ciklopropankarboksilne kiseline [5-(4-fenilaminometil-fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il]-amid ciklopropankarboksilne kiseline (5-{4-[3-(acetil-metil-amino)-pirolidin-1-ilmetil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline {5-[4-(3-dimetilamino-pirolidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(3,3-difluoro-pirolidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline (5-{4-[3-(4-cijano-fenoksimetil)-azetidin-1-ilmetil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline {5-[4-(2-okso-2-piperidin-1-il-etil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline (5-{4-[2-(1,1-diokso-tiomorfolin-4-il)-2-okso-etil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline 4-[2-(ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-benzilamid ciklobutankarboksilne kiseline {5-[4-(3-dimetilamino-piperidin-1-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(3-hidroksi-piperidin-1-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(3,3-difluoro-pirolidin-1-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline 4-[2-(ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-benzilamid ciklopropankarboksilne kiseline 4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-N-(1,1-diokso-tetrahidrotiofen-3-il)-N-metil-benzamid amid 1-{4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-benzoil}-piperidin-4-karboksilne kiseline amid 1-{4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-benzoil}-piperidin-2-karboksilne kiseline {5-[4-(3-hidroksimetil-piperidin-1-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(3-okso-piperazin-1-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline (5-{4-[3-(4-cijano-fenoksi)-azetidin-1-ilmetil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline tert-butil ester (1-{4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-benzil}-azetidin-3-il)-karbamske kiseline {5-[4-(3-fluoro-piperidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(4-metoksi-piperidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline ciklopropankarboksilne kiseline {5-[4-(4-etoksi-piperidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid (5-{4-[3-(acetil-metil-amino)-azetidin-1-ilmetil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline ciklopropankarboksilne kiseline (5-{4-[3-(4-cijano-benziloksi)-azetidin-1-il]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid {5-[4-(3-dietilamino-pirolidin-1-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(4-hidroksi-4-fenil-piperidin-1-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(3-acetilamino-azetidin-1-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(3-cijano-azetidin-1-il)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(3-dimetilamino-pirolidin-1-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline (5-{4-[3-(piperidin-1-karbonil)-piperidin-1-karbonil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline {5-[4-(3-dimetilamino-azetidin-1-ilmetil)-fenil][1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline (5-{4-[4-(piridin-3-iloksimetil)-piperidin-1-karbonil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline {5-[4-(4-metoksi-piperidin-1-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(4-etoksi-piperidin-1-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline dietilamid 1-{4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-benzoil}-piperidin-3-karboksilne kiseline {5-[4-(3-acetilamino-piperidin-1-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline (5-{4-[acetil-(6-cijano-piridin-3-ilmetil)-amino]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline {5-[4-(3-dimetilaminometil-azetidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline dimetilamid 1-{4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[[1,5-a]piridin-5-il]-benzil}-azetidin-3-karboksilne kiseline {5-[4-(3-morfolin-4-il-azetidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(4-cijanometil-fenoksimetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(izoksazol-3-ilaminometil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(3-cijano-azetidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline (5-{4-[(1,1-diokso-tetrahidro-tiofen-3-ilamino)-metil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline {5-[4-((S)-3-hidroksi-pirolidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline 2-{4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-benzilamino}-benzamid {5-[4-((R)-3-hidroksi-pirolidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline 4-[2-(ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-benzilamid 4-metil-piperazin-1-karboksilne kiseline 4-[2-(ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-benzilamid morfolin-4- karboksilne kiseline tert-butil ester (1-{4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-benzil}-piperidin-4-il)-karbamske kiseline {5-[4-(3-okso-piperazin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline [5-(4-ciklopropilaminometil-fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il]-amid ciklopropankarboksilne kiseline {5-[4-(3-hidroksi-piperidin-1ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(3,3-dimetil-azetidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(3,3-difluoro-azetidin-1-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(piridin-3-ilcarbamoilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline (5-{4-[2-(3,3-difluoro-azetidin-1-il)-2-okso-etil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline {5-[4-(2-azetidin-1-il-2-okso-etil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline (5-{4-[2-okso-2-(4-trifluorometil-piperidin-1-il)-etil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline (5-{4-[2-(3,5-dimetil-piperidin-1-il)-2-okso-etil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline (5-{4-[2-(3-metoksi-azetidin-1-il)-2-okso-etil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline (5-{4-[2-(3-acetilamino-azetidin-1-il)-2-okso-etil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline (5-{4-[2-(4-acetilamino-piperidin-1-il)-2-okso-etil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline dimetilamid 1-(2-{4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-fenil}-acetil)-azetidin-3-karboksilne kiseline (5-{4-[3-(4-cijano-benziloksi)-azetidin-1-karbonil]-fenil}-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid ciklopropankarboksilne kiseline {5-[4-(3-morfolin-4-il-azetidin-1-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(3-dimetilamino-azetidin-1-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(3-cijano-azetidin-1-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline {5-[4-(3-dimetilaminometil-azetidin-1-karbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid ciklopropankarboksilne kiseline 4-[2-(Ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-N-(1H-1,2,4-triazol-3-il)-benzamid.
9. Spoj za uporabu prema zahtjevu 1, naznačen time da bolest je reumatoidni artritis.
10. Spoj za uporabu prema zahtjevu 1, naznačen time da bolest uključuje pogoršanje promjena u hrskavici koja je odabrana od osteoartritisa, psorijatičnog artritisa, juvenilnog reumatoidnog artritisa, gihta, septičkog ili infekcijskog artritisa, reaktivnog artritisa, refleksne simpatičke distrofije, algodistrofije, Tietzeovog sindroma ili rebrenog hondritisa, fibromijalgije, osteohondroze, neurogenog ili neuropatskog artritisa, artropatije, endemskih oblika artritisa kao endemskog deformacijskog osteoartritisa, Mseleni bolesti i Handigodu bolesti; degeneracije koja potiče od fibromijalgije, sistemskog eritemskog lupusa, skleroderma i ankilozni spondilitis.
11. Spoj za uporabu prema zahtjevu 1, naznačen time da bolest je odbacivanje transplantata.
HRP20140681AT 2008-07-25 2014-07-15 Novi spojevi korisni za lijeäśenje degenerativnih i upalnih bolesti HRP20140681T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13592008P 2008-07-25 2008-07-25
US22068509P 2009-06-26 2009-06-26
PCT/EP2009/059604 WO2010010190A1 (en) 2008-07-25 2009-07-24 Novel compounds useful for the treatment of degenerative and inflammatory diseases

Publications (1)

Publication Number Publication Date
HRP20140681T1 true HRP20140681T1 (hr) 2014-10-24

Family

ID=41021059

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20130357AT HRP20130357T1 (en) 2008-07-25 2013-04-23 Novel compounds useful for the treatment of degenerative and inflammatory diseases.
HRP20140681AT HRP20140681T1 (hr) 2008-07-25 2014-07-15 Novi spojevi korisni za lijeäśenje degenerativnih i upalnih bolesti

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20130357AT HRP20130357T1 (en) 2008-07-25 2013-04-23 Novel compounds useful for the treatment of degenerative and inflammatory diseases.

Country Status (36)

Country Link
US (5) US8853240B2 (hr)
EP (2) EP2346864B1 (hr)
JP (2) JP5480261B2 (hr)
KR (2) KR101711911B1 (hr)
CN (2) CN102105471B (hr)
AR (1) AR072875A1 (hr)
AU (2) AU2009273143B2 (hr)
BR (2) BRPI0916862B8 (hr)
CA (2) CA2730762C (hr)
CL (1) CL2009001637A1 (hr)
CO (1) CO6361925A2 (hr)
CR (1) CR20110092A (hr)
CY (2) CY1113945T1 (hr)
DK (2) DK2346864T3 (hr)
DO (1) DOP2011000022A (hr)
EA (2) EA018587B1 (hr)
ES (2) ES2406691T3 (hr)
HK (2) HK1158634A1 (hr)
HR (2) HRP20130357T1 (hr)
IL (2) IL210262A (hr)
JO (1) JO3041B1 (hr)
MA (1) MA32551B1 (hr)
ME (1) ME02046B (hr)
MX (2) MX2011000756A (hr)
MY (1) MY157615A (hr)
NZ (1) NZ590646A (hr)
PE (1) PE20100152A1 (hr)
PL (2) PL2346864T3 (hr)
PT (2) PT2361251E (hr)
RS (2) RS53406B (hr)
SI (2) SI2361251T1 (hr)
SM (2) SMT201300051B (hr)
TW (1) TWI447118B (hr)
UY (1) UY32006A (hr)
WO (2) WO2010010191A1 (hr)
ZA (2) ZA201100396B (hr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
EP2438066A2 (en) 2009-06-05 2012-04-11 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES
CA2708690A1 (en) * 2009-06-26 2010-12-26 Markus Braun Process for producing cellulose beads from solutions of cellulose in ionic liquid
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
WO2011140333A1 (en) 2010-05-07 2011-11-10 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
WO2012000970A1 (en) 2010-07-01 2012-01-05 Cellzome Limited Triazolopyridines as tyk2 inhibitors
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
WO2014004376A2 (en) 2012-06-26 2014-01-03 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US9169214B2 (en) * 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
CN103965114B (zh) * 2013-01-28 2016-01-06 苏州泽璟生物制药有限公司 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
EP2951590A1 (en) 2013-02-04 2015-12-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
CN105339370B (zh) * 2013-06-19 2017-09-15 加拉帕戈斯股份有限公司 用于治疗炎症性疾病的化合物和及其药物组合物
EP3083583B1 (en) 2013-12-20 2020-11-18 Sagimet Biosciences Inc. Heterocyclic modulators of lipid synthesis and combinations thereof
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3179857B1 (en) 2014-08-14 2021-09-08 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
TWI679205B (zh) 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
AU2016212526B2 (en) 2015-01-28 2020-11-05 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd Substituted imidazo (1, 2-a) pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
WO2016165953A1 (en) * 2015-04-13 2016-10-20 Galapagos Nv Methods for the treatment of inflammatory disorders
UA119701C2 (uk) * 2015-04-29 2019-07-25 Вуксі Фортуне Фармасьютікал Ко., Лтд Піримідинові сполуки як jak-інгібітори
AU2016257892A1 (en) * 2015-05-05 2017-11-09 Concert Pharmaceuticals, Inc. Deuterated filgotinib
CN105061420B (zh) * 2015-06-04 2017-09-05 南京旗昌医药科技有限公司 一种jak抑制剂的晶型及其制备方法和应用
CN104987333B (zh) * 2015-07-14 2017-01-11 苏州富士莱医药股份有限公司 一种Filgotinib的合成方法
WO2017012770A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Acid addition salts of filgotinib
WO2017012773A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Solid forms of filgotinib free base
WO2017012771A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Crystalline filgotinib sulfonic acid addition salts
CN105218539B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物b晶型及其制备方法
CN105198878B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物f晶型及其制备方法
CN105111207B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物d晶型及其制备方法
CN105198880B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物a晶型及其制备方法
CN105111206B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物e晶型及其制备方法
CN105198876B (zh) * 2015-09-18 2017-09-29 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物h晶型及其制备方法
CN105198877B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物g晶型及其制备方法
CN105198879B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物c晶型及其制备方法
WO2017133423A1 (zh) * 2016-02-02 2017-08-10 深圳市塔吉瑞生物医药有限公司 一种取代的吡啶酰胺类化合物及其应用
TWI712604B (zh) 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶
US11279699B2 (en) 2016-07-26 2022-03-22 Suzhou Longbiotech Pharmaceuticals Co., Ltd. Compound as selective JAK inhibitor, and salt and therapeutic use thereof
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN107880038B (zh) * 2016-09-30 2021-09-28 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
JOP20190077A1 (ar) * 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
CA3039208A1 (en) * 2016-10-26 2018-05-03 Janssen Pharmaceutica Nv Fused azaheterocyclic compounds and their use as ampa receptor modulators
SG11201902884YA (en) * 2016-10-26 2019-05-30 Janssen Pharmaceutica Nv Fused bicylic pyridine compounds and their use as ampa receptor modulators
EA039352B1 (ru) * 2017-01-19 2022-01-17 Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. Соединение в качестве селективного ингибитора jak и его соли и терапевтическое применение
CN108341814B (zh) * 2017-01-23 2021-09-03 上海翔锦生物科技有限公司 Jak激酶抑制剂及其应用
BR112019016935A2 (pt) 2017-02-17 2020-04-07 Eidos Therapeutics Inc processos para preparação de ag-10, seus intermediários e sais dos mesmos
GB201702603D0 (en) 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
US11427581B2 (en) 2018-01-31 2022-08-30 Zhuhai United Laboratories Co., Ltd. JAK inhibitor and use thereof
CN111788204B (zh) 2018-02-26 2023-05-05 吉利德科学公司 作为hbv复制抑制剂的取代吡咯嗪化合物
EP3758700A4 (en) * 2018-02-28 2021-11-17 University of Southern California COMPOSITIONS AND METHODS OF MODULATING INFLAMMATORY AND DEGENERATIVE DISORDERS
AU2019239291A1 (en) 2018-03-23 2020-10-08 Eidos Therapeutics, Inc. Methods of treating TTR amyloidosis using AG10
AU2019321583A1 (en) 2018-08-17 2021-01-21 Eidos Therapeutics, Inc. Formulations of AG10
AU2019326647B2 (en) * 2018-08-23 2022-02-10 Zhuhai United Laboratories Co., Ltd. (1,2,4)triazolo(1,5-a)pyridine compound as JAK inhibitor and application thereof
US10815227B2 (en) 2018-08-27 2020-10-27 Cadila Healthcare Limited Processes for the preparation of filgotinib
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US20230391768A2 (en) * 2018-11-07 2023-12-07 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor
JP2022540200A (ja) 2019-07-11 2022-09-14 エスケイプ・バイオ・インコーポレイテッド Ｌｒｒｋ２阻害剤としてのインダゾールおよびアザインダゾール
CN111892592B (zh) * 2019-08-06 2023-09-19 江苏柯菲平医药股份有限公司 Jak激酶抑制剂及其用途
CN111072655B (zh) * 2019-12-30 2021-12-10 深圳市坤健创新药物研究院 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
KR20220127900A (ko) * 2020-02-13 2022-09-20 주하이 유나이티드 라보라토리즈 컴퍼니 리미티드 Jak 키나아제 관련 질병의 치료를 위한 약물의 제조에 있어서 jak 억제제의 용도
US20230091250A1 (en) * 2020-02-21 2023-03-23 Zhuhai United Laboratories Co., Ltd. Crystalline form of jak inhibitor and application thereof
WO2021226261A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN111617318B (zh) * 2020-05-26 2021-12-10 南京市儿童医院 可注射型儿童骺板再生水凝胶的制备方法
CN114394965B (zh) * 2021-01-29 2023-09-12 深圳市乐土生物医药有限公司 三唑并吡啶类化合物及其制备方法与用途
AU2022388555A1 (en) 2021-11-09 2024-05-02 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN113773322B (zh) * 2021-11-10 2022-02-11 奥锐特药业(天津)有限公司 一种Filgotinib的制备方法
CN116496268A (zh) * 2022-01-18 2023-07-28 盛世泰科生物医药技术(苏州)有限公司 一种含环丙酰胺化合物及其应用
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics
US11746108B1 (en) * 2022-06-13 2023-09-05 Apm Therapeutics 1, Inc. Triazolopyridine polymorph A

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4058243B2 (ja) * 1999-01-29 2008-03-05 中外製薬株式会社 軟骨形成促進剤およびインドリン−２−オン誘導体
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
DE602004001676T2 (de) 2003-02-14 2007-08-30 Pfizer Products Inc., Groton Triazolo-Pyridine als entzündungshemmende Verbindungen
TWI221602B (en) * 2003-07-21 2004-10-01 Benq Corp Emergent disc-withdrawing apparatus
US20050222171A1 (en) * 2004-01-22 2005-10-06 Guido Bold Organic compounds
ES2427136T3 (es) 2004-06-21 2013-10-29 Galapagos N.V. Métodos y medios para el tratamiento de la osteoartritis
JP2008509987A (ja) 2004-08-18 2008-04-03 ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー トリアゾロピリジン化合物
JP2008515874A (ja) 2004-10-07 2008-05-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌薬
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
BRPI0716239A2 (pt) * 2006-08-30 2013-08-13 Cellzome Ltd derivados de triazol como inibidores de cinase
WO2008065198A1 (en) * 2006-12-01 2008-06-05 Galapagos N.V. Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases
CL2008001626A1 (es) * 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
CN101801966A (zh) * 2007-07-18 2010-08-11 诺瓦提斯公司 双环杂芳基化合物和它们作为激酶抑制剂的用途
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
EP2181112A1 (en) * 2007-08-31 2010-05-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US8811196B2 (en) * 2008-02-19 2014-08-19 Qualcomm Incorporated Providing remote field testing for mobile devices
US20090217316A1 (en) * 2008-02-22 2009-08-27 Binita Gupta Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service
JP5595389B2 (ja) 2008-06-20 2014-09-24 ジェネンテック， インコーポレイテッド トリアゾロピリジンｊａｋ阻害剤化合物と方法
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010186A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
PT2391435E (pt) * 2009-02-02 2014-01-23 Basf Se Agente de absorção contendo aminas cíclicas para a remoção de gases ácidos
DE102009000543A1 (de) * 2009-02-02 2010-08-12 Evonik Degussa Gmbh Verfahren, Absorptionsmedien und Vorrichtung zur Absorption von CO2 aus Gasmischungen
EP2438066A2 (en) 2009-06-05 2012-04-11 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
SG10201700125VA (en) 2012-06-22 2017-02-27 Galapagos Nv Aminotriazolopyridine For Use In The Treatment Of Inflammation, And Pharmaceutical Compositions Thereof

Also Published As

Publication number Publication date
IL210261A (en) 2017-03-30
BRPI0916862B8 (pt) 2021-05-25
US10206907B2 (en) 2019-02-19
ME02046B (me) 2015-05-20
IL210262A (en) 2014-09-30
PL2361251T3 (pl) 2014-10-31
AU2009273143A1 (en) 2010-01-28
PT2361251E (pt) 2014-07-11
BRPI0916659B8 (pt) 2021-05-25
KR20110053435A (ko) 2011-05-23
PE20100152A1 (es) 2010-03-24
CO6361925A2 (es) 2012-01-20
PL2346864T3 (pl) 2013-08-30
IL210262A0 (en) 2011-03-31
JP2011529033A (ja) 2011-12-01
WO2010010190A1 (en) 2010-01-28
US9415037B2 (en) 2016-08-16
SMT201400072B (it) 2014-09-08
SI2346864T1 (sl) 2013-05-31
KR101676391B1 (ko) 2016-11-15
ZA201100396B (en) 2011-10-26
AR072875A1 (es) 2010-09-29
DK2346864T3 (da) 2013-05-13
EA018587B1 (ru) 2013-09-30
MX2011000758A (es) 2011-02-23
EA201170257A1 (ru) 2011-08-30
RS52823B (en) 2013-10-31
CA2730762A1 (en) 2010-01-28
AU2009273144A1 (en) 2010-01-28
NZ590646A (en) 2011-11-25
CL2009001637A1 (es) 2010-02-19
ES2485913T3 (es) 2014-08-14
BRPI0916862A2 (pt) 2016-02-10
EA201170255A1 (ru) 2011-08-30
CN102105471B (zh) 2014-10-15
US8242274B2 (en) 2012-08-14
BRPI0916659A2 (pt) 2019-03-12
AU2009273144B2 (en) 2013-10-31
EP2361251A1 (en) 2011-08-31
RS53406B (en) 2014-10-31
BRPI0916659B1 (pt) 2020-12-08
CA2730762C (en) 2017-11-21
DOP2011000022A (es) 2011-03-31
AU2009273143B2 (en) 2014-01-23
WO2010010191A1 (en) 2010-01-28
MY157615A (en) 2016-06-30
TW201008939A (en) 2010-03-01
US20100029709A1 (en) 2010-02-04
UY32006A (es) 2010-02-26
EP2346864B1 (en) 2013-03-06
ES2406691T3 (es) 2013-06-07
CY1113945T1 (el) 2016-07-27
CA2730757A1 (en) 2010-01-28
JP5480261B2 (ja) 2014-04-23
SMT201300051B (it) 2013-07-09
US20150150856A1 (en) 2015-06-04
CN102105472B (zh) 2013-04-17
JO3041B1 (ar) 2016-09-05
BRPI0916862B1 (pt) 2020-08-11
CN102105472A (zh) 2011-06-22
HK1158635A1 (en) 2012-07-20
IL210261A0 (en) 2011-03-31
US20110190260A1 (en) 2011-08-04
US8853240B2 (en) 2014-10-07
CR20110092A (es) 2011-03-16
JP5559168B2 (ja) 2014-07-23
US20120309784A1 (en) 2012-12-06
MX2011000756A (es) 2011-03-21
US20170035738A1 (en) 2017-02-09
HK1158634A1 (en) 2012-07-20
JP2011529032A (ja) 2011-12-01
PT2346864E (pt) 2013-04-04
ZA201100472B (en) 2011-10-26
TWI447118B (zh) 2014-08-01
EA018080B1 (ru) 2013-05-30
CN102105471A (zh) 2011-06-22
HRP20130357T1 (en) 2013-05-31
EP2346864A1 (en) 2011-07-27
MA32551B1 (fr) 2011-08-01
SI2361251T1 (sl) 2014-09-30
EP2361251B1 (en) 2014-04-30
DK2361251T3 (da) 2014-07-21
KR20110045020A (ko) 2011-05-03
CY1115569T1 (el) 2017-01-04
KR101711911B1 (ko) 2017-03-03

Similar Documents

Publication Publication Date Title
HRP20140681T1 (hr) Novi spojevi korisni za lijeäśenje degenerativnih i upalnih bolesti
US8470816B2 (en) Nitrogen-containing heterocyclic compound and use thereof
AU2007212236B2 (en) Piperidinyl derivatives as modulators of chemokine receptor activity
US6858623B2 (en) Compounds useful as reversible inhibitors of cysteine proteases
EP2426109B1 (en) Novel kinase inhibitors
AU2007263809B2 (en) Tetrazole-substituted arylamides
US8450317B2 (en) CXCR3 receptor antagonists
US8435978B2 (en) Substituted sulfonamide compounds
KR20110031318A (ko) Ｉａ 심부전 및 암 치료에 유용한 단백질 키나제 ｄ 억제제로서의 2,4'-비피리디닐 화합물
RU2009116670A (ru) Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
US20050256159A1 (en) 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors
US20130029971A1 (en) Cxcr3 receptor antagonists
JP5444547B2 (ja) Ｌｘｒ調節因子としてのｎ−ベンジル，ｎ’−アリールカルボニルピペラジン誘導体
US20060142337A1 (en) Piperidine derivative and use thereof
AU2009271003A1 (en) Imidazolylpyrimidine compounds as HDAC and/or CDK inhibitors
HRP20020221A2 (en) Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
JP2011518836A5 (hr)
JP2012519196A (ja) スルホニル化されたテトラヒドロアゾロピラジンおよびその医薬としての使用
JP2013515026A (ja) 置換されたベンズアミド誘導体
CA2764956A1 (en) Novel biphenyl and phenyl-pyridine amides
JP6182602B2 (ja) １−［ｍ−カルボキサミド（ヘテロ）アリール−メチル］−ヘテロシクリル−カルボキサミド誘導体
JP5552539B2 (ja) Ｃｎｓ障害の処置のためのオキサゾリン誘導体
JP2010539204A (ja) 小分子ブラジキニンｂ１受容体アンタゴニスト
CN101541802A (zh) 取代的2,5-二氢-3h-吡唑并[4,3-c]哒嗪-3-酮的衍生物、其制备和其在治疗中的用途
WO2007089031A1 (en) Piperidine derivatives as tachykinin receptor antagonists